-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
1.
1.
On the same day, 211 public medical institutions at the second level and above in six cities conducted intense negotiations with 29 manufacturing companies on three types of medical consumables such as synthetic bone.
After more than 4 hours of quotation and negotiation, the average drop rate of the three types of products: synthetic bone, cord anchor nail, and non-absorbable clip under endoscope was 67%, 52%, 72%, and the highest drop was 73%.
On April 24, the Suzhou Municipal Medical Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:
The companies to be selected for synthetic bones include Nade, Tianjin Saining Biotechnology, etc.
The companies to be selected for the line anchor include Johnson & Johnson, Xeroxhui, Ruishi, etc.
The companies that will be selected for single-issue non-absorbable clips under endoscopy include Zhejiang Weidu, Jiangsu Sanlian Xinghai, and Telif.
According to news from Modern Express, Wang Xiaoping, Director of the Medical Price and Bidding and Purchasing Division of the Suzhou Medical Insurance Bureau, said that the alliance negotiations were carried out on the basis of the volume price negotiations of the Suzhou, Yancheng, and Suqian alliances.
The total purchase volume this time has doubled compared with the purchase volume in the three cities in 2019.
As the first city in Jiangsu Province to explore the volume procurement of high-value consumables by regional alliances, in 2019, Suzhou, Yancheng, and Suqian cross-regional "group purchase" of high-value consumables, and achieved remarkable results in reducing the burden of medical treatment.
2.
2.
Products for price negotiation with quantity include artificial synthetic bone (bone pellets, bone blocks), cord anchors (Ti alloy, peek, absorbable), single-shot non-absorbable clips under endoscope and other products.
According to official WeChat messages from the Suzhou Medical Insurance Bureau and the Yancheng Medical Insurance Center, on November 22, 2019, the volume price negotiation of the consumables alliance of public medical institutions in Suzhou, Yancheng, and Suqian was conducted at the Suzhou Public Resource Exchange Center.
After more than 5 hours of quotation and negotiation, finally:
Synthetic bone was negotiated by the manufacturer, and the selected varieties had an average drop of 41.
The wire anchors were quoted and negotiated separately for individual varieties, and the average drop of the selected varieties was 31.
The average drop rate of single-shot non-absorbable clips under endoscopy was 43.
27%, and the highest drop rate was 55.
29%;
After the negotiation, a representative of the selected machinery company said: "We have let the price of synthetic bone particles by about 40%.
It used to be about 6,000 yuan per gram, and now it is about 3,000 yuan per gram.
"
In addition, on March 22 this year, the Jinling Evening News reported that the Nanjing Medical Insurance Bureau signed a continuation confirmation letter for the results of the overall procurement negotiations with related companies, and continued to innovate the management method of "packaged price reduction" of medical consumables in Nanjing.
It is understood that in 2019, the Nanjing Medical Insurance Bureau conducted overall procurement negotiations with three well-known medical consumables companies, and the prices of all medical consumables won by the companies involved in the Nanjing area dropped by 25%-30%.
After the renewal, the overall negotiation will be based on 70% of the previous usage by the medical institution, and the minimum purchase amount will be agreed.
3.
Artificial bone: Chinese and foreign companies coexist, and domestic products are on the rise
Artificial bone: Chinese and foreign companies coexist, and domestic products are on the rise
In the field of orthopedics, bone defects due to severe trauma, bone tumors, osteomyelitis and other reasons are very common.
Currently commonly used bone repair materials include autogenous bone and metal prosthesis.
The autogenous bone increases the trauma and pain of the patient; the metal prosthesis has problems such as loosening and fracture.
Therefore, artificial bone replacement material transplantation to repair bone defects has become the focus of medicine.
Artificial bone refers to artificial biological materials that can replace human bone or repair bone tissue defects.
Artificial bone is one of the consumables purchased this time.
According to an industry report by Grand View Research, the global bone graft and substitute market in 2018 is estimated to be US$2.
58 billion, and is expected to grow at a compound annual growth rate of 4.
1% during the forecast period.
The increasing number of spinal fusion surgeries, the target population and the adoption of allografts are the main growth drivers for this market
According to data from the United Nations Department of Population and Economic Affairs, the number of people over 60 in 2013 was 841 million, and it is expected to reach 2 billion in 2050.
Therefore, with the increase of the elderly population, the incidence of orthopedic diseases will be greatly increased, which will bring about a large amount of orthopedic surgery, which will also greatly stimulate the demand for artificial bone tissue materials.
According to data from China Industry Information Network, the demand for my country's bone repair materials industry in 2017 was about 36,800 grams, an increase of 17.
95% from 31,200 grams in 2016.
The orthopedic implant industry in my country presents a market competition pattern in which Chinese and foreign companies coexist and foreign-funded companies dominate.
Most enterprises in the orthopedic implant industry in my country are small in scale, weak in research and development capabilities, and weak in market competitiveness.
Foreign-funded enterprises have entered the Chinese orthopedic implant market earlier by virtue of their advantages in technology, brand, and capital, and have occupied a favorable market competitive position.
Multinational companies such as Zimmer, Medtronic, Stryker, Johnson & Johnson and others account for more than 70% of the market for orthopedic implants in my country.
According to the analysis of China Industry Information Network, in the context of continuous technological innovation in the industry and the continuous improvement of domestic enterprises’ own technology, technology and R&D capabilities, a number of market-competitive and large-scale orthopedic implants have emerged in the Chinese orthopedic implant market.
Local enterprises, such as Dabo Medical Technology Co.
, Ltd.
, Shandong Weigao Orthopedic Materials Co.
, Ltd.
, Jiangsu Ideal Medical Technology Co.
, Ltd.
, Beijing Chunlizhengda Medical Equipment Co.
, Ltd.
, etc.
annex: